Skip to content
PeptideWADA Status UnclearCompare

Thymosin Alpha-1

Also known as: Ta1, Zadaxin, Thymalfasin, TA-1

1
1 · Natty510 · Enhanced

Lower numbers = closer to natural. Higher numbers = more enhanced.

Why this rating?

Thymosin Alpha-1 is an immunomodulatory peptide that supports immune function. Per Garaci et al. and clinical studies, it promotes T cell maturation and enhances NK cell cytotoxicity. However, it does NOT directly build muscle, burn fat, or enhance athletic performance. It is purely for immune/health support. Approved in 35+ countries for hepatitis and cancer adjunct therapy. Rated 1 (basically natty) because it does not move the muscular/physique ceiling by any path - it only supports immune function toward baseline, with no anabolic, fat-loss, or hormonal effect.

Overview

A 28-amino acid immunomodulatory peptide derived from thymus gland. Functions as immune modulator (not stimulant) - shifts responses toward homeostasis rather than amplifying. Promotes T cell maturation, enhances NK cell cytotoxicity, stimulates dendritic cell function via TLR signaling. Extensive clinical use internationally for hepatitis B/C, cancer adjunct, sepsis, and immunodeficiency. Excellent safety profile with minimal side effects.

Important Warnings

  • •NOT FDA-approved - orphan drug designation only
  • •Sourcing quality variable - pharmaceutical grade (Zadaxin) difficult to obtain
  • •Will NOT directly build muscle or burn fat
  • •Benefits are subtle and supportive - not performance enhancing
  • •Theoretical caution in autoimmune diseases (may modulate immune activity)
  • •Insufficient pregnancy/lactation data
  • •Short half-life requires frequent dosing
  • •Limited direct evidence for athletic applications (extrapolated from clinical data)

Purpose & Use Cases

Immune Support During Intense Training

Supports immune function during overreaching phases. May reduce infection risk. Counteracts exercise-induced immune suppression.

Contest Prep Health Maintenance

Caloric restriction suppresses immune function. Ta1 may help maintain immunity during cuts, reducing illness during critical prep phases.

Hepatitis B/C (Clinical)

Approved internationally for HBV. Increases HBeAg seroconversion 30-40% vs 15-20% control. Synergistic with interferon-alpha.

Cancer Adjunct Therapy (Clinical)

Restores immune function during chemo/radiation. Reduces infections, improves quality of life, some survival benefits. Used in NSCLC, HCC, melanoma.

Sepsis/Critical Illness (Clinical)

May reduce mortality in severe sepsis - the ETASS RCT showed a trend toward lower 28-day mortality (roughly 26% vs 35%) that did not reach statistical significance; later meta-analyses suggest benefit. Restores lymphocyte counts. Used in some countries for severe COVID-19.

Benefits

  • Excellent safety profile - over 20 years post-marketing data
  • Promotes T cell maturation and function
  • Enhances NK cell cytotoxicity
  • Stimulates dendritic cell antigen presentation
  • No significant drug interactions
  • No hepatotoxicity or nephrotoxicity
  • Approved in 35+ countries with extensive clinical data
  • Does not interfere with hormonal systems or PCT
  • Well-tolerated long-term

Good to Know

An immune modulator, not an immune stimulant

Thymosin Alpha-1 (thymalfasin) is a 28-amino-acid thymic peptide that signals through Toll-like receptors (notably TLR9 on dendritic cells) to recalibrate T-cell maturation and the Th1/Th2 balance toward homeostasis. It nudges the immune system toward balance rather than simply amplifying it, which is why it is used both to shore up weak immunity and in inflammatory/sepsis settings.

It is an approved drug in much of the world, but not the US

Unlike most research peptides, Ta1 (brand Zadaxin) is an actual approved medicine in 35+ countries for chronic hepatitis B/C and as an immune adjunct, with 20+ years of post-marketing safety data. In the US it has orphan-drug designation only (never FDA-approved); the FDA restricted compounding-pharmacy access via Category 2 of the 503A bulks list in late 2023 (the same list that caught BPC-157), but that restriction was lifted in September 2024, and HHS moved it back to Category 1 in February 2026, restoring the legal compounding pathway.

The physique angle is staying healthy, not getting bigger

Ta1 does not build muscle, burn fat, or affect the HPTA (no PCT), so it rates a 2. Its practical use for a lifter is immune maintenance during periods that suppress immunity, heavy training blocks and the caloric deficit of contest prep, to reduce illness that would derail progress.

Theoretical caution if you have an autoimmune condition

Because Ta1 modulates immune activity, there is a theoretical concern about using it with autoimmune disease. Its safety record is excellent overall, but the athletic/recovery use is extrapolated from clinical (hepatitis/oncology/sepsis) data rather than proven in healthy athletes.

Dosage Guidelines

Experience LevelDosage Range
Beginner900 – 1800 mcg/week
Intermediate1800 – 3200 mcg/week
Advanced3200 – 3200 mcg/week
Frequency
Standard/RCT-proven protocol is 2x weekly subcutaneous injections - figures above are the WEEKLY TOTAL, not a single dose (e.g. 1.6mg/dose x 2/week = 3.2mg/week is the exact regimen used in the pivotal hepatitis B trials). Some community maintenance protocols spread doses 2-3x weekly instead. Short intensive/loading courses (daily or EOD, 5-14 days) used during acute illness are NOT reflected in the typical ranges above - see notes.
Typical Cycle Length
4 – 24 weeks
Notes

The RCT-proven clinical regimen is 1.6mg (1600mcg) SC twice weekly = 3.2mg/week, validated in chronic hepatitis B trials (Chien RN et al. 1998, PMID 9581695) and used similarly in oncology/sepsis studies. Lower community "maintenance"/immune-support protocols commonly run 450-900mcg per shot, 2x weekly (900-1800mcg/week). Intensive/loading protocol (community-derived, not RCT-established): up to 1600mcg SC daily or every-other-day for 5-14 days during acute illness or a heavy training/illness-risk block, then taper back to twice-weekly maintenance. The short elimination half-life (~2 hours) is why dosing is frequent rather than once-weekly; immune-marker changes build over roughly the first week of dosing. Reconstitute with sterile or bacteriostatic water.

Half-Life

Range roughly 1.5-3 hours; plasma levels return to baseline within ~8-12 hours.

Side Effects

Injection Site Reactions

common
Severity
1/5

5-15% incidence across trials. Mild redness, swelling, or induration at the injection site.

Mitigation

Rotate injection sites.

Flu-like Symptoms

uncommon
Severity
1.5/5

5-10% incidence. Low-grade fever, malaise. Indicates immune activation.

Mitigation

Usually transient. May reduce with continued use.

Fatigue

uncommon
Severity
1/5

5-10% incidence. Mild tiredness.

Mitigation

Usually resolves. Consider evening dosing.

Headache

uncommon
Severity
1/5

~5% incidence.

Mitigation

Usually mild and transient.

Myalgia

rare
Severity
1/5

<5% incidence. Mild muscle aches.

Mitigation

Usually transient.

General Mitigation Strategies

Ta1 has an excellent safety profile with no dose-limiting toxicities at standard doses. No significant lab abnormalities, no hepatotoxicity, no nephrotoxicity, no bone marrow suppression. Safe in renal/hepatic impairment. Long-term use (>12 months) appears safe. Theoretical caution in autoimmune diseases.

Support Supplements

Ancillary supplements commonly run alongside Thymosin Alpha-1 to manage side effects, support the target tissue, or fill nutrient demands it creates.

Vitamin D3

Foundational immune-support nutrient; adequate vitamin D status supports T-cell and innate immune function, complementing Ta1's immune-modulating role. Deficiency blunts immune competence.

Dose
~1,000-5,000 IU/day, titrated to a 25(OH)D in range
Timing
Daily with a fat-containing meal
When
General immune support rather than a Ta1-specific requirement.

Zinc

Cofactor for T-cell development and overall immune function; a common marginal deficiency in dieting athletes.

Dose
~15-30mg/day (keep zinc:copper balanced)
Timing
With food; separate from high-dose iron/calcium
When
Support nutrient, not a treatment; avoid chronic high-dose zinc (can drive copper deficiency).

Post Cycle Therapy (PCT)

✓PCT Not Required

Does not affect HPT axis or hormonal systems. No interference with PCT. Can be used during any phase of a cycle or PCT without hormonal impact.

How It Works

Acts primarily through Toll-like receptors (TLR2, TLR5, TLR9), activating NF-κB and IRF signaling pathways. Promotes T cell maturation (CD4+/CD8+), increases IL-2 and IL-2R expression, shifts Th1/Th2 balance toward Th1. Enhances NK cell cytotoxicity and numbers. Stimulates dendritic cell maturation, MHC I/II expression, and co-stimulatory molecules (CD80, CD86). Increases IFN-α, IFN-γ, IL-2, IL-10, IL-12.

Fundamentals

Reference on the practices relevant to Thymosin Alpha-1: how they are done and where they go wrong. Not a recommendation to use it.

Reconstitution & concentration math→

Turning this powder into a measured dose

Sterile technique & injection-site infection→

Avoiding abscesses and cellulitis

Bloodwork: what to measure and when→

The markers that matter here

Warning signs & when to seek care→

When to stop and get help

Common Stacks

  • Ta1 + BPC-157 + TB-500 - comprehensive recovery/health stack
  • Ta1 during contest prep - immune support during caloric deficit
  • Ta1 during heavy training blocks - reduce infection risk
  • Ta1 does not interfere with any PEDs or PCT compounds
  • Can be used year-round for health maintenance

WADA Status

❓WADA Status Unclear

Thymosin Alpha-1 is not specifically named on the WADA Prohibited List, and unlike unapproved research peptides it is an actual licensed medicine (Zadaxin) in 35+ countries, which weakens the case for it being swept in under S0 ("non-approved substances"). It is also not a growth factor/GH secretagogue, so S2 does not appear to apply either. That said, status is not formally confirmed by WADA for this specific peptide, so tested athletes should verify with their federation before use.

References

Last updated: July 19, 2026